Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/16/24
End: 06/30/26
Due: 06/30/27
Phase: N/A
Priority: Normal
Start: 12/27/19
End: 01/10/22
Due: 01/10/23
Phase: N/A
Priority: Normal
Start: 10/01/21
End: 02/18/25
Due: 02/18/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | NCT06745583 | Elixiron Immunotherapeutics (Hong Kong) Ltd. | user2@example.com | None | 2024-12-16 | 2026-06-30 | 2027-06-30 | - | - | 2025-07-14 |
| A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers | NCT04238364 | Elixiron Immunotherapeutics (Hong Kong) Ltd. | user2@example.com | None | 2019-12-27 | 2022-01-10 | 2023-01-10 | - | - | 2025-07-14 |
| First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers | NCT04994912 | Elixiron Immunotherapeutics (Hong Kong) Ltd. | user2@example.com | None | 2021-10-01 | 2025-02-18 | 2026-02-18 | - | - | 2025-07-14 |